Clinical Trial Update: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

A randomized Phase II trial comparing rituximab plus pentostatin versus rituximab plus bendamustine in multiply relapsed or refractory hairy cell leukemia; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Pentostatin (pentostatin)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-05-01